Patient characteristics
| Characteristic . | No. (%) or median (range) . |
|---|---|
| Male sex | 16 (57) |
| Age, y | 64 (41-80) |
| Organ involvement | |
| Heart | 22 (79) |
| Kidney | 11 (39) |
| Soft tissues | 5 (18) |
| Peripheral nervous system | 4 (14) |
| Liver | 1 (4) |
| Performance status (ECOG) | |
| 0 | 2 (7) |
| 1 | 11 (39) |
| 2 | 14 (50) |
| 3 | 1 (4) |
| Cardiac stage* | |
| I | 6 (21) |
| II | 14 (50) |
| IIIa | 6 (21) |
| IIIb | 2 (8) |
| NYHA class III | 11 (39) |
| Renal stage† | |
| I | 20 (71) |
| II | 8 (29) |
| III | 0 (0) |
| Bone marrow plasma cell infiltrate, % | 12 (4-34) |
| dFLC, mg/L | 153 (75-2972) |
| dFLC > 180 mg/L | 12 (43) |
| Previous treatment lines | 2 (1-7) |
| Previous treatment | |
| Bortezomib | 27 (96) |
| Melphalan‡ | 21 (75) |
| Cyclophosphamide | 19 (68) |
| Lenalidomide | 7 (25) |
| Thalidomide | 4 (14) |
| Ixazomib | 4 (14) |
| Bendamustine | 3 (11) |
| Characteristic . | No. (%) or median (range) . |
|---|---|
| Male sex | 16 (57) |
| Age, y | 64 (41-80) |
| Organ involvement | |
| Heart | 22 (79) |
| Kidney | 11 (39) |
| Soft tissues | 5 (18) |
| Peripheral nervous system | 4 (14) |
| Liver | 1 (4) |
| Performance status (ECOG) | |
| 0 | 2 (7) |
| 1 | 11 (39) |
| 2 | 14 (50) |
| 3 | 1 (4) |
| Cardiac stage* | |
| I | 6 (21) |
| II | 14 (50) |
| IIIa | 6 (21) |
| IIIb | 2 (8) |
| NYHA class III | 11 (39) |
| Renal stage† | |
| I | 20 (71) |
| II | 8 (29) |
| III | 0 (0) |
| Bone marrow plasma cell infiltrate, % | 12 (4-34) |
| dFLC, mg/L | 153 (75-2972) |
| dFLC > 180 mg/L | 12 (43) |
| Previous treatment lines | 2 (1-7) |
| Previous treatment | |
| Bortezomib | 27 (96) |
| Melphalan‡ | 21 (75) |
| Cyclophosphamide | 19 (68) |
| Lenalidomide | 7 (25) |
| Thalidomide | 4 (14) |
| Ixazomib | 4 (14) |
| Bendamustine | 3 (11) |
All of the patients were refractory to the last line of treatment administered before PDex.
ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pronatriuretic peptide type B; NYHA, New York Heart Association.
Cardiac stage is defined by NT-proBNP (cutoff, 332 ng/L) and cardiac troponin I (cutoff, 0.1 ng/mL); stage I, II, and III patients have none, 1, or 2 markers greater than the cutoff, respectively. In stage IIIb patients, NT-proBNP is > 8500 ng/L.
Renal stage is defined by eGFR (cutoff, 50 mL/min per 1.73 m2) and proteinuria (cutoff, 5 g/24 h); stage I patients have both eGFR greater than and proteinuria less than the cutoff, stage II have either eGFR less than or proteinuria greater than the cutoff, and stage III patients have both eGFR less than and proteinuria greater than the cutoff.
Six patients (21%) underwent autologous stem cell transplantation.